Europe's Pharma Tries To 'Keep Calm And Carry On' Amid Storm Strikes
Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.
You may also be interested in...
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.